Table 4.
Calculated pharmacological values for aortic ring constrictor and relaxation response
| Treatment Group | EC50 (nM) | Hill slope | ||||
|---|---|---|---|---|---|---|
| PE | ACh | SNP | PE | ACh | SNP | |
| Naive | 565.9 ± 129.8 | 127.4 ± 19.4 | 104.1 ± 25.3 | 1.7 ± 0.2 | 1.8 ± 0.3 | 2.1 ± 0.4 |
| 1 Day Post IT Exposure | ||||||
| Citrate | 501.9 ± 125.4 | 108.8 ± 47.0 | 74.3 ± 29.5 | 1.8 ± 0.2 | 1.4 ± 0.3 | 1.8 ± 0.2 |
| 20 nm AgNP | 311.4 ± 58.1 | 97.79 ± 17.9 | 28.6 ± 8.0 | 1.7 ± 0.1 | 1.5 ± 0.1 | 1.8 ± 0.2 |
| 110 nm AgNP | 558.5 ± 122.2 | 58.45 ± 18.1 | 20.9 ± 4.2 | 1.7 ± 0.2 | 1.8 ± 0.5 | 1.8 ± 0.3 |
| PVP | 450.2 ± 60.3 | 101.9 ± 20.7 | 44.8 ± 4.8a | 1.5 ± 0.0 | 1.7 ± 0.1 | 1.7 ± 0.1 |
| 20 nm AgNP | 593.0 ± 161.8 | 121.6 ± 31.9 | 40.5 ± 10.6a | 1.9 ± 0.4 | 1.6 ± 0.1 | 1.8 ± 0.2 |
| 110 nm AgNP | 490.8 ± 156.2 | 119.3 ± 20.1 | 20.9 ± 4.2a | 1.7 ± 0.2 | 1.7 ± 0.4 | 1.9 ± 0.4 |
| 7 Day Post IT Exposure | ||||||
| Citrate | 497.6 ± 11.8 | 106.1 ± 57.9 | 26.4 ± 6.6a | 1.8 ± 0.2 | 1.8 ± 0.2 | 1.7 ± 0.2 |
| 20 nm AgNP | 256.2 ± 58.0 | 63.4 ± 7.4 | 45.1 ± 1.0a | 1.6 ± 0.1 | 1.6 ± 0.1 | 1.6 ± 0.2 |
| 110 nm AgNP | 540.4 ± 18.0 | 84.2 ± 26.3 | 66.3 ± 29.3 | 1.6 ± 0.1 | 1.6 ± 0.1 | 1.8 ± 0.1 |
| PVP | 215.0 ± 15.0 | 196.6 ± 82.2 | 40.1 ± 18.8 | 1.1 ± 0.1 | 1.5 ± 0.4 | 1.7 ± 0.4 |
| 20 nm AgNP | 122.9 ± 14.1a | 120.0 ± 13.2 | 66.6 ± 14.9 | 1.1 ± 0.1 | 1.1 ± 0.2 | 1.5 ± 0.2 |
| 110 nm AgNP | 260.3 ± 50.0 | 66.2 ± 17.7 | 66.4 ± 10.6 | 1.1 ± 0.0 | 2.0 ± 0.3 | 1.5 ± 0.4 |
The calculated mean EC50, and Hill slope, responses of aorta segment to phenylephrine (PE), acetylcholine (ACh), and sodium nitroprusside (SNP) 1 day and 7 days post 200 μl instillation of Citrate or PVP vehicle or 200 μg 20 or 110 nm AgNP. Values expressed mean ± SEM. adenotes significant versus Naïve (p < 0.05) calculated by one-way ANOVA with Tukey Post Hoc test, n = 3–8